Avalyn Pharma (AVLN) Stock Price & Analysis
Score
AI Analysis
SnapshotAvalyn Pharma Inc. Common Stock is a growth-led story right now — Growth 100/100 is the pillar doing the heavy lifting (overall 71/100) in Biotechnology. In Biotechnology, that score mix is usable but not one-dimensional. Street targets still imply ~98% upside.
Price History
Price: —
Fair value: —
—
P/E (TTM): —
Net Income (TTM): —
Score: —
—
Score Breakdown
Market percentile scores loading…
Value
Growth
Quality
Financial Summary
Avalyn Pharma Inc. Common Stock (AVLN) last printed $30.28. Equity value is $1.35B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.
Financials
| 2024 | 2025 |
|---|---|
| $0.00 | $0.00 |
About
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.